These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 3036388)

  • 1. In vitro evaluation of a new nitrosourea, TCNU, against human small cell lung cancer cell lines.
    Roed H; Vindeløv LL; Spang-Thomsen M; Christensen IJ; Hansen HH
    Cancer Chemother Pharmacol; 1987; 19(4):315-8. PubMed ID: 3036388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tauromustine, a water-soluble nitrosourea compound on NMU-1 murine lung tumor.
    Pratesi G; Savi G
    Oncology; 1989; 46(2):132-5. PubMed ID: 2710478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of TCNU in patients with squamous, adeno and large cell carcinoma of the lung.
    Vibe-Petersen J; Bach F; Pedersen AG; Smyth J; Hansen HH
    Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1881-5. PubMed ID: 2561100
    [No Abstract]   [Full Text] [Related]  

  • 4. Chemotherapy with tauromustine in advanced non-small cell lung cancer. A trial of the Phase II Study Group of the Association for Medical Oncology of the German Cancer Society.
    Gatzemeier U; Drings P; Edler L; Fiebig HH; Hinke A; Rieche K; Tessen HW
    Onkologie; 1990 Jun; 13(3):186-8. PubMed ID: 2168534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved antitumor effect of the nitrosourea drugs tauromustine (TCNU) and carmustine (BCNU) on a rat liver adenocarcinoma after hepatic arterial administration with degradable starch microspheres.
    Roos G; el Hag IA; Teder H; Stenram U
    Anticancer Res; 1991; 11(1):13-6. PubMed ID: 2018346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCNU in adenocarcinoma of the lung: a phase II study with divided doses.
    Sørensen JB; Bach F; Dombernowsky P; Vibe-Petersen J; Hansen HH
    Ann Oncol; 1990 Jul; 1(4):299-300. PubMed ID: 2265139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a novel taurine nitrosourea, 1-(2-chloroethyl)-3-[2-(dimethylaminosulfonyl)ethyl]-1-nitrosour ea (TCNU) on cytotoxicity, DNA crosslinking and glutathione reductase in lung carcinoma cell lines.
    Tew KD; Dean SW; Gibson NW
    Cancer Chemother Pharmacol; 1987; 19(4):291-5. PubMed ID: 2954712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nitrosourea combinations in lung cancer.
    Livingston RB
    Cancer Treat Rep; 1976 Jun; 60(6):757-760. PubMed ID: 182365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of TCNU, a novel nitrosourea.
    Smyth JF; Macpherson JS; Warrington PS; Kerr ME; Whelan JM; Cornbleet MA; Leonard RC
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1845-9. PubMed ID: 3436348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TCNU: a ray of hope for designer nitrosoureas?
    Workman P
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1823-8. PubMed ID: 3325292
    [No Abstract]   [Full Text] [Related]  

  • 11. Activity of a new nitrosourea (TCNU) in human lung cancer xenografts.
    Fergusson RJ; Anderson LE; Macpherson JS; Robins P; Smyth JF
    Br J Cancer; 1988 Apr; 57(4):339-42. PubMed ID: 3390369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tumour, toxicological and pharmacokinetic properties of a novel taurine-based nitrosourea (TCNU).
    Hartley-Asp B; Christensson PI; Gunnarsson K; Gunnarsson PO; Jensen G; Polacek J; Stamvik A
    Invest New Drugs; 1988 Apr; 6(1):19-30. PubMed ID: 3410663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can human small-cell lung cancer cell lines be applied for optimizing chemotherapy?
    Roed H; Vindeløv LL
    Cancer Treat Res; 1989; 45():151-72. PubMed ID: 2577171
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-tumour activity of TCNU in a panel of transplantable murine colon tumours.
    Bibby MC; Double JA; Morris CM
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1361-4. PubMed ID: 3181257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TCNU (LS 2667), a new active drug in the treatment of advanced colorectal cancer. EORTC Early Clinical Trials Group.
    Gundersen S; Dombernowsky P; Cavalli F; Bruntsch U; Renard J; Van Glabbeke M; Pinedo H
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1095-7. PubMed ID: 2759163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tauromustine is more effective than conventional chemotherapy in the treatment of colonic tumors.
    Singh G; Graffner HO; Milsom JW; Chaudry IH
    Dis Colon Rectum; 1993 Apr; 36(4):394-9. PubMed ID: 8458268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of TCNU in advanced breast cancer.
    Dombernowsky P; Clavel M; Smyth JF; Howell A; van Glabekke M; Renard J; Pinedo HM
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1377-8. PubMed ID: 3181260
    [No Abstract]   [Full Text] [Related]  

  • 18. A phase I clinical evaluation of 1-(2-chloroethyl)-3-[2-(dimethylaminosulphonyl)ethyl]-1-nitrosou rea (TCNU).
    Vibe-Petersen J; Bork E; Møller H; Hansen HH
    Eur J Cancer Clin Oncol; 1987 Dec; 23(12):1837-43. PubMed ID: 3436347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro and in vivo responses of a panel of murine colon tumours to TCNU: a positive correlation.
    Phillips RM; Bibby MC; Double JA
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1365-71. PubMed ID: 3181258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of tauromustine in disseminated malignant melanoma.
    Nolte H; Gjedde SB; Lindegaard-Madsen E; Bergh J; Blomquist E; Mouridsen HT
    Eur J Cancer Clin Oncol; 1989 Apr; 25(4):655-7. PubMed ID: 2714342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.